4 stories mentioning HTFL
Every FINWIRES story that references HTFL, newest first.
John C.M. Farquhar, Director, Chief Executive Officer, on May 11, 2026, sold 22,562 shares in Heartflow (HTFL) for $657,005. Following the Form 4 filing with the SEC, Farquhar has control over a total of 519,397 common shares of the company, with 519,397 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000067/xslF345X05/form4.xml
Heartflow, Inc. (HTFL) has an average rating of Buy and mean price target of $37.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
John C.M. Farquhar, Director, Chief Executive Officer, on April 10, 2026, sold 22,562 shares in Heartflow (HTFL) for $602,857. Following the Form 4 filing with the SEC, Farquhar has control over a total of 549,163 common shares of the company, with 549,163 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1464521/000146452126000055/xslF345X05/form4.xml
Heartflow (HTFL) said Monday it has lodged a patent infringement complaint against Cleerly in a Texas district court regarding the unapproved application of its coronary artery disease technology.Heartflow alleges that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe six of its patents, according to a statement.Cleerly did not immediately respond to' request for a comment.Price: $26.31, Change: $-0.64, Percent Change: -2.37%